Approval · Notice of Compliance 20799 · 2018
MVASI: Notice of Compliance 20799
Issued April 30, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20799
- Date
- April 30, 2018
- Company
- Amgen Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
Medicinal ingredients
- BEVACIZUMAB 25 MG per ML